Get started
Author

Shifra Ash

Colorectal Carcinoma in Childhood: A Retrospective Multicenter Study
2007 · Dragan Kravarusic, Elad Feigin, et al. · Journal of Pediatric Gastroenterology and Nutrition · 56
Delayed diagnosis and treatment of children with cancer during the COVID-19 pandemic
2021 · Michal Dvori, Sarah Elitzur, et al. · International Journal of Clinical Oncology · 31
PDF
Additional chromosome 1q aberrations and der(16)t(1;16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors
1997 · Batia Stark, Celia Mor, et al. · Journal of Neuro-Oncology · 25
Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
2013 · Myriam Weyl Ben-Arush, Ayelet Ben Barak, et al. · PubMed · 13
Infectious Mononucleosis in Hospitalized Patients Over Forty Years of Age
1988 · Jonathan Halevy, Shifra Ash · The American Journal of the Medical Sciences · 13
Profiles of parental coping with paediatric cancer and their associations with parental illness adaptation
2024 · Nadya Golfenshtein, Lamia Barakat, et al. · Journal of Advanced Nursing · 11
Acinic Cell Carcinoma of the Parotid Gland in Children and Adolescents
2017 · Shifra Ash, Isaac Yaniv, et al. · Journal of Pediatric Hematology/Oncology · 10
War and peace: Israeli physicians treating Palestinian patients
2023 · Shifra Ash, Tsila Zuckerman, et al. · The Lancet · 5
PDF
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison
2025 · Holger N. Lode, Przemysław Holko, et al. · Cancers · 4
PDF
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025 · Holger N. Lode, Nikolai Siebert, et al. · Clinical Cancer Research · 3
PDF
Gaps in pediatric oncologic end of life care as recounted by the bereaved parents in Isarel
2023 · Irit Schwartz-Attias, Shifra Ash, et al. · Journal of Pediatric Nursing · 2
Pediatric Langerhans Cell Histiocytosis of Bone: A systematic review of the unknown mechanism of self-healing
2025 · Dana Ashkenazi Lustig, Shifra Ash, et al. · Pediatric Hematology Oncology Journal · 1
Renal Cell Carcinoma in a Child Presented as Bilateral Femur Neck Fractures Caused by Severe Vitamin D Deficiency
2007 · Shraga Aviner, Dan Dabby, et al. · Journal of Pediatric Hematology/Oncology · 1
Treatment of Neuroblastoma Using the Fused Imaging Guided Radiotherapy (FIGURA) System
2006 · Eyal Fenig, Moshe Mishaeli, et al. · Clinical Nuclear Medicine · 1
Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
2026 · Holger N. Lode, Przemysław Holko, et al. · Biomedicines
Figure 1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S1 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Data from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Figure 2 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Figure 3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S4 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Table S3 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Supplementary Figure S6 from Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma
2026 · Nurit Gal-Mark, Assaf Grunwald, et al.
Works count: 56
Citation count: 176
H-index: 7
I10-index: 7
Year
Topic
Type